BSLN — Basilea Pharmaceutica AG Allschwil Cashflow Statement
0.000.00%
- CH₣521.16m
- CH₣496.36m
- CH₣208.54m
- 44
- 62
- 94
- 79
Annual cashflow statement for Basilea Pharmaceutica AG Allschwil, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -14.7 | -6.83 | 12.1 | 10.5 | 77.6 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | -9.84 | 5.84 | 5.54 | 6.53 | 6.08 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -30.8 | -31.8 | -11.7 | -4.32 | 6.29 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -54.1 | -32 | 7.06 | 14.2 | 74.4 |
Capital Expenditures | -2.27 | -0.86 | -3.3 | -1.03 | -1.79 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -32.7 | 4.43 | 95 | 0 | 0.781 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -35 | 3.58 | 91.6 | -1.03 | -1.01 |
Financing Cash Flow Items | -3.19 | — | — | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 45.1 | 16.6 | -45.2 | -57.3 | -13.2 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -44.8 | -11.3 | 53.6 | -44.2 | 60.2 |